



Five reasons to choose Devyser RHD


 **100,000**
 **Rh-negative**
 **mothers analyzed**

Proven in routine clinical use, Devyser RHD has been used to analyze many expectant mothers and help them receive truly personalized care.



99.99% sensitivity


A study with a large cohort of 2,300 samples found Devyser RHD had exceptional diagnostic sensitivity¹.




**37% reduction
in unnecessary
treatment**

Studies demonstrate Devyser RHD can help 37% of Rh-negative mothers avoid unnecessary treatment¹. This closely matches the estimated 40% of Rh-negative mothers exposed to unnecessary cost and risks of anti-D treatments.

Optimized for automated, high throughput screening



Devyser RHD uses a single step protocol, with limited hands-on time or manual steps, and allows automated DNA extraction and plate setup methods to be used easily.



Easy to implement

The kit comes with all necessary PCR reagents, and the assay is compatible with multiple real-time PCR instruments. The assay can be used with samples that have been frozen for up to 13 months, and fresh samples stored at room temperature for up to 7 days.

CE-IVD is available in the EU and countries outside EU accepting the CE-IVD certification. Available as RUO in all other countries.

1. Isakson P, Pardi C. Evaluation of an automated platform for non-invasive single-exon fetal RHD genotyping early in pregnancy. Blood Transfus. 2023;21(6):472-478.